Aurobindo Pharma Prioritizes Returns, Halts Greenfield Capex for Profitability
Loading more articles...
Aurobindo Pharma Shifts Strategy: Focus on Returns, Steps Back from Greenfield Capex
C
CNBC TV18•16-02-2026, 13:37
Aurobindo Pharma Shifts Strategy: Focus on Returns, Steps Back from Greenfield Capex
•Aurobindo Pharma is shifting its strategy to improve profitability ratios and returns, moving away from large greenfield expansion.
•The company will focus on better utilization of existing assets and pursue only small acquisitions that directly boost EBITDA margins.
•Key operational triggers for next year include the Penicillin-G plant, an acquisition closure, production at the Dayton plant, and a turnaround in the China facility.
•The Penicillin-G plant has already ramped up production and turned profitable, with January output nearly meeting PLI requirements.
•Aurobindo's US arm, Acrotech Biopharma, received US FDA approval for a dermatology drug, marking its entry into innovative treatments with significant market potential.
